Legend Biotech (LEGN) Capital Expenditures (2020 - 2026)

Legend Biotech (LEGN) has 8 years of Capital Expenditures data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Capital Expenditures rose 275.0% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 115.21% YoY) and the FY2024 annual result came in at $14.1 million, down 29.77% from the prior year.
• Capital Expenditures rose to $7.5 million in Q1 2026, from -$5.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $35.8 million in Q4 2023 to a low of -$20.9 million in Q4 2022.
• A 5-year average of $579437.5 and a median of $276500.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 2680.0% — and 2025, when it sank 4583.39%.
• Tracing LEGN's Capital Expenditures over 5 years: stood at -$20.9 million in 2022, then surged by 271.18% to $35.8 million in 2023, then retreated by 27.89% to $25.8 million in 2024, then tumbled by 119.38% to -$5.0 million in 2025, then soared by 249.85% to $7.5 million in 2026.
• The last three Capital Expenditures figures came in at $7.5 million (Q1 2026), -$5.0 million (Q3 2025), and -$13.2 million (Q2 2025), per Business Quant data.